Home

CNC — Deck

Centene Corporation · CNC · NYSE

Centene is the largest US Medicaid managed-care insurer, also the largest ACA Marketplace carrier and the largest stand-alone Medicare Part D plan, earning a few hundred basis points of medical-cost discipline on $195B of government-program premium revenue.

$41.82
Price (Apr 24, 2026)
$20.6B
Market cap
$194.8B
Revenue (FY25)
27.6M
Members across 30 states
Listed Dec 2001; rode the post-ACA managed-care wave to a split-adjusted ~$93 peak in 2022, collapsed to $25 in July 2025 on the Marketplace blow-up, and has clawed back to $42.
2 · The tension

One ratio runs this stock — does HBR mean-revert from 91.9% back toward 88%

  • The whole P&L fits in one number. About 92¢ of every premium dollar pays medical claims, ~7¢ pays SG&A, and ~1¢ is operating profit. FY25 Health Benefits Ratio jumped from 88.3% to 91.9% — every 100 bps swing is ~$1.7B pre-tax. From 91.9% back to 88% rebuilds $6–7B of pre-tax earnings.
  • Bull math is mechanical. 95%+ of the 2026 Marketplace book is repriced at +mid-30%, Medicaid composite rate update is +5.5%, and Medicare Advantage Stars jumped from 23% to 60% in 3.5+ plans in two years — locking in 2027–2028 bonus revenue today.
  • Bear math is permanent. The same actuaries set both the 2025 misprice and the 2026 rates. OBBBA work requirements arrive Dec 2026, state-directed-payment caps phase down 10pp/yr from Jan 2028, and EAPTC expiration plausibly costs the Marketplace 4.8M lives — together a 100–200 bps structural step-up in HBR.
91.9% is either a cyclical peak or the new floor. The same management told both stories within twelve months.
3 · The $13.53 loss that produced $4.3B of cash

The GAAP catastrophe is overwhelmingly a non-cash write-down of acquisitions paid for years ago

$194.8B
Revenue FY25 +19% YoY
−$13.53
GAAP EPS $6.7B goodwill write-down
$2.08
Adjusted EPS FY25 Guide >$3.00 for 2026
$4.3B
Free cash flow from −$490M in FY24

Strip the $6.7B Q3 goodwill impairment and FY25 was breakeven on $195B of premium — the operating wound is real but smaller than the GAAP picture. Operating cash leads earnings by 12–18 months in a float-driven insurer: the FY24 receivables build that crashed cash flow to $154M unwound this year, producing $5.1B of OCF. P/S of 0.11× is the lowest in the company's 20-year public history (median 0.74×); forward P/E is 14× on the consensus $3 of 2026 EPS.

4 · Forensic watch

One disclosure decides whether the $5.1B cash recovery is real or engineered

  • $4.0B Part D receivable facility. Signed Feb 13, 2026; permits sale of CMS Part D risk-sharing receivables booked as a sale of A/R, with the discount running through SG&A. The capacity equals 79% of FY25 operating cash flow. Undrawn at filing — every 10-Q footnote either confirms the cash recovery or breaks it.
  • Reserve direction is wrong. Days-in-claims-payable fell from 53 to 46 days while HBR rose 360 bps — claims paying faster while costs accelerate. The Medicare Advantage premium-deficiency reserve cycled $0 → $389M → $0 inside a single year, with the release flowing back to adjusted EPS. Both patterns precede reserve catch-ups, not recoveries.
  • Adjusted-EPS bridge larger than the loss. The 'other adjustments' line stripped $14.86 per share to bridge from −$13.53 GAAP to $2.08 adjusted — itself bigger than the GAAP loss. The audit opinion is clean; the size of the judgment estimates is not.
Forensic grade today is 48 / Elevated. A draw on the $4B facility tips it to High. An undrawn balance through the FY26 10-K removes the largest bear anchor.
5 · The catalyst

Tomorrow's pre-market print is the cleanest test of the whole thesis in two years

  • Q1 2026, April 28 pre-market. Consensus: $1.85 adjusted EPS, $47.5B revenue, blended HBR 89.3%. Q4 2025 Marketplace HBR was 95.4% — the first read on whether the +mid-30% rate hikes worked. Sub-89% Marketplace with Medicaid ≤93% reaffirms the floor; the inverse replays July 2025's $7.25 → $1.75 guide cut.
  • Then 90 quiet days. May 12 annual meeting carries say-on-pay and a shareholder proposal mandating an independent chair; mid-May 10-Q is the first $4B facility disclosure window; Goldman and Jefferies healthcare conferences land early June; Q2 print in late July is the second confirmation.
  • The market priced the EPS, not the multiple. Consensus has $3 of EPS in 2026 at 14× — a $42 target. UnitedHealth trades at 19.6×, Molina at 33.7×, Elevance at 13.5×. Centene at the trough multiplier on the lowest P/S in its 20-year history is the asymmetry the consensus target ignores.
Three of four variant views resolve inside 90 days. The deck of catalysts is unusually short and unusually empirical.
6 · Bull and Bear

Lean long, wait for the print — the math is mechanical, the trust isn't

  • For. Market cap ($20.6B) sits below 10-year cumulative free cash flow ($28.2B). P/S 0.11× has never been lower in twenty years (median 0.74×). Each 100 bps of HBR mean-reversion adds ~$1.7B pre-tax — a sub-1% margin business reverting to its 20-year band is a double.
  • For. Medicare Advantage Stars rebuilt 23% → 60% in 3.5+ in two years — the operationally hardest move in managed care. The 2027–2030 D-SNP integration mandate funnels dual-eligibles to incumbent Medicaid carriers; Centene's 12.5M Medicaid members across 30 states is the largest such footprint and is priced as zero.
  • Against. The same actuaries who missed 2025 morbidity by $2.4B in a single quarter set 2026 Marketplace prices. $7.25 EPS was reaffirmed in April 2025 and cut to $1.75 by July — a 76% reversal on the two issues management said it had under control.
  • Against. Hagens Berman securities class action (filed July 2025) is in pre-trial discovery with a June 8 bar date; SEC matter referenced separately. Q4 2025 13Fs: Norges Bank −69%, UBS AM −76%, activist Politan −70% — the largest concentrated ownership rotation in years.
My view — the cheap-with-open-SEC-matter is real but not actionable until Q1/Q2 prints clear. The flip condition is mechanical: Medicaid HBR ≤93%, Marketplace HBR ≤88%, the $4B facility undrawn through the FY26 10-K.

Watchlist to re-rate: Marketplace HBR (sub-89% reaffirms repricing); Medicaid HBR (≤93% means rate-catch-up is working); $4B Part D receivable facility utilization in each 10-Q footnote; CEO and CFO Form 4 activity once the class action clears.